Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 13/20 | 0.47 |
| ▸ | EGFR | P00533 | 6/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.46 |
| ▸ | ABL1 | P00519 | 3/20 | 0.44 |
| ▸ | BCR | P11274 | 3/20 | 0.44 |
| ▸ | MAP2K1 | Q02750 | 1/20 | 0.43 |
| ▸ | STK4 | Q13043 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13500129 | 0.96 | SRC (0.46) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL13427175 | 0.85 | SRC (0.48) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL13427176 | 0.81 | SRC (0.47) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL13427186 | 0.77 | SRC (0.53) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL15150223 | 0.74 | MAP3K8 (0.45) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL13485435 | 0.72 | KDR (0.46) | SRCEGFRERBB2 | |
| SCHEMBL13485492 | 0.71 | EGFR (0.41) | SRCEGFRERBB2 | |
| SCHEMBL6384016 | 0.71 | SRC (0.81) | SRCEGFRERBB2ABL1BCR | |
| Hydrochloric Acid SCHEMBL6384369 | 0.70 | SRC (0.80) | SRCEGFRERBB2ABL1BCR | |
| SCHEMBL15150221 | 0.69 | MAP3K8 (0.44) | SRCEGFRERBB2ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9365517-B2 | 3-cyano-quinoline derivatives with antiproliferative activity | JANSSEN PHARMACEUTICA NV (BE) | 2016-06-14 | — | — | US | disclosed |
| US-9040511-B2 | 3-cyano-quinoline derivatives with antiproliferative activity | JANSSEN PHARMACEUTICA NV (BE) | 2015-05-26 | — | — | US | disclosed |
| US-20140256948-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | JANSSEN PHARMACEUTICA NV (BE) | 2014-09-11 | — | — | US | disclosed |
| US-8778920-B2 | 3-cyano-quinoline derivatives with antiproliferative activity | JANSSEN PHARMACEUTICA NV (BE) | 2014-07-15 | — | — | US | disclosed |
| US-20130197022-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | JANSSEN PHARMACEUTICA N.V. (BE) | 2013-08-01 | — | — | US | disclosed |
| US-7655642-B2 | e.g. 7-bromo-23-methoxy-12-oxo-10,11,12,13,14,15,16,17,18,19-decahydro-5H-1,21-(ethanediylidene)pyrido[4,3-b][6,1,10,13]benzoxatriazacyclooctadecine-4-carbonitrile; tyrosine kinase, angiogenesis inhibitor; growth factors (epidermal, fibroblast, platelet, endothelial) antagonist; antiproliferative agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2010-02-02 | — | — | US | disclosed |
| US-20080139601-A1 | e.g. 7-bromo-23-methoxy-12-oxo-10,11,12,13,14,15,16,17,18,19-decahydro-5H-1,21-(ethanediylidene)pyrido[4,3-b][6,1,10,13]benzoxatriazacyclooctadecine-4-carbonitrile; tyrosine kinase, angiogenesis inhibitor; growth factors (epidermal, fibroblast, platelet, endothelial) antagonist; antiproliferative agent | JANSSEN PHARMACEUTICA N.V. (BE) | 2008-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256948-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | NR1H3, NR1H2, NR1D1 | SRC 1724/4885EGFR 3349/4885ERBB2 2568/4885 |
| US-20130197022-A1 | 3-CYANO-QUINOLINE DERIVATIVES WITH ANTIPROLIFERATIVE ACTIVITY | NR1H3, NR1H2, NR1D1 | SRC 1724/4885EGFR 3349/4885ERBB2 2568/4885 |
| US-20080139601-A1 | e.g. 7-bromo-23-methoxy-12-oxo-10,11,12,13,14,15,16,17,18,19-decahydro-5H-1,21-(ethanediylidene)pyrido[4,3-b][6,1,10,13]benzoxatriazacyclooctadecine-4-carbonitrile; tyrosine kinase, angiogenesis inhibitor; growth factors (epidermal, fibroblast, platelet, endothelial) antagonist; antiproliferative agent | KDR, PDGFRB, NR1H2 | SRC 269/4885EGFR 27/4885ERBB2 45/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.